Abstract

Fetal/neonatal alloimmune thrombocytopenia (FNAIT) resulting from fetal platelet destruction by maternal alloantibodies is the most common cause of severe fetal thrombocytopenia and of neonatal thrombocytopenia in maternity wards.1  The pathophysiology is largely unknown. The fetus has long been considered as an “innocent bystander.”

In this issue of Blood, Chen and colleagues, using murine models, demonstrate that the fetal, not maternal, major histocompatibility complex class I–related neonatal Fc receptor (FcRn) is implicated in the transplacental transfer of maternal antibodies and show that monoclonal antibody specific to FcRn may be effective in this disease.2 

FcRn a key factor in FNIT. (A) Fetal FcRn is required for FNIT. Low platelet counts are observed only in pups expressing fetal FcRn delivered from immunized β3−/−FcRn−/− × β3+/+FcRn−/+. (B) Anti-FcRn monoclonal antibody injection during pregnancy. Low platelet counts are observed only in pups delivered from nontreated immunized female mice. N = platelet counts. (Professional illustration by Paulette Dennis.)

FcRn a key factor in FNIT. (A) Fetal FcRn is required for FNIT. Low platelet counts are observed only in pups expressing fetal FcRn delivered from immunized β3−/−FcRn−/− × β3+/+FcRn−/+. (B) Anti-FcRn monoclonal antibody injection during pregnancy. Low platelet counts are observed only in pups delivered from nontreated immunized female mice. N = platelet counts. (Professional illustration by Paulette Dennis.)

FNAIT (1/1000 live births) is usually discovered incidentally.3  The complication most feared is intracranial hemorrhage, leading to death or neurologic sequelae.4  If the fetus in a subsequent pregnancy is also platelet antigen incompatible, the condition is usually more severe, so antenatal management has been proposed with weekly maternal administration of intravenous immunoglobulins (IVIG).5  This treatment is relatively effective. However, this therapy relies on a human-derived product; it is expensive and in some cases therapy failures have been observed. Other approaches are therefore under study.6 

Chen et al focus on the FcRn receptor, its role in the pathophysiology of fetal/neonatal immune thrombocytopenia (FNIT) and as a possible target for therapy. In fetal medicine, direct human research is usually not possible for ethical reasons. To address these questions the authors have developed several knockout murine models7  and monoclonal antibodies. The model they established is more similar to human platelet isoimmunization (the recipient lacks glyco-protein) than alloimmunization (immunization resulting from single amino-acid substitution); however, the major clinical effect of interest, that is, thrombocytopenia, is present in pups.

FcRn was characterized in the 1980s. This receptor is involved in the specific transport of IgG from the mother to the fetus. In rodents, FcRn is expressed on the cell-surface brush border of enterocytes. It has been shown that FcRn functions most efficiently in the neo-natal period when pups ingest maternal milk containing IgG.8  In humans, the maternal IgG transfer occurs antenatally via the placenta.

To identify more accurately the mechanisms responsible for mediating the transport of IgG maternal antibodies, Chen et al established a new model of FNIT using combined β3/FcRn-deficient mice. They document that anti-β3 integrin antibodies could be generated and maintained at a relatively high level in double β3/FcRn knockout mice immunized with β3 platelets. They demonstrate that FcRn is essential in the cross-placental passage of maternal antibodies by showing β3−/+FcRn+/+ pups having lower platelet counts than heterozygous β3 pups lacking FcRn. Chen and colleagues also reviewed the respective roles of maternal and fetal FcRn, clearly showing that fetal FcRn was the predominant effector for transplacental IgG transport and the resulting induction of low platelet counts in pups (see figure, panel A); in addition, they investigated whether FcRn may be a therapeutic target in FNIT.

Throughout life, FcRn plays a critical role in regulating the levels and persistence of IgG. Modulating the interaction of IgG with FcRn allows development of a new therapy in antibody-mediated diseases.9  To address this specific issue, Chen et al produced a new anti-FcRn monoclonal antibody. They found that pups delivered from anti-β3–immunized female mice treated with this antibody have higher platelet counts than those delivered from nontreated immunized mice (see figure, panel B), suggesting that such an antibody may be considered as a therapeutic agent.

The last part of the study examines the potential role of FcRn in the mechanisms involved in the action of IVIG.10  Reports favor saturation of FcRn, leading to increased catabolism of pathogenic antibodies.

Chen et al show that IVIG is able to down-regulate anti-β3 antibodies in immunized female mice—also in the absence of FcRn—and to increase platelet counts in pups delivered from IVIG-treated mice. This article makes new contributions, establishing that fetal FcRn is a key factor in the transplacental passage of maternal antibodies and may be considered as a potential therapeutic target. However, translating these results from murine models to humans should be done with caution; open questions remain. The placental structure varies remarkably across species. Humans and mice express different Fc receptors and FcRn-IgG interactions may differ between species. Animal models expressing human receptors and in vitro studies using human placental lobules are to be considered.

Conflict-of-interest disclosure: The author declares no competing financial interests. ■

References

References
1
Dreyfus
 
M
Kaplan
 
C
Verdy
 
E
, et al. 
Frequency of immune thrombocytopenia in newborns: a prospective study.
Blood
1997
, vol. 
89
 
12
(pg. 
4402
-
4406
)
2
Chen
 
P
Li
 
C
Lang
 
S
, et al. 
Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy.
Blood
2010
, vol. 
116
 
18
(pg. 
3660
-
3668
)
3
Durand-Zaleski
 
I
Schlegel
 
N
Blum-Boisgard
 
C
, et al. 
Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs.
Am J Perinatol
1996
, vol. 
13
 
7
(pg. 
423
-
431
)
4
Mueller-Eckhardt
 
C
Kiefel
 
V
Grubert
 
A
, et al. 
348 cases of suspected neonatal alloimmune thrombocytopenia.
Lancet
1989
, vol. 
1
 
8634
(pg. 
363
-
366
)
5
Berkowitz
 
RL
Lesser
 
ML
McFarland
 
JG
, et al. 
Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial.
Obstet Gynecol
2007
, vol. 
110
 
2 Pt 1
(pg. 
249
-
255
)
6
Ghevaert
 
C
Wilcox
 
DA
Fang
 
J
, et al. 
Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.
J Clin Invest
2008
, vol. 
118
 
8
(pg. 
2929
-
2938
)
7
Ni
 
H
Chen
 
P
Spring
 
CM
, et al. 
A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy.
Blood
2006
, vol. 
107
 
7
(pg. 
2976
-
2983
)
8
Jones
 
EA
Waldmann
 
TA
The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat.
J Clin Invest
1972
, vol. 
51
 
11
(pg. 
2916
-
2927
)
9
Sesarman
 
A
Vidarsson
 
G
Sitaru
 
C
The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.
Cell Mol Life Sci
2010
, vol. 
67
 
15
(pg. 
2533
-
2550
)
10
Crow
 
AR
Lazarus
 
AH
The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?
Transfus Med Rev
2008
, vol. 
22
 
2
(pg. 
103
-
116
)